ImmunityBio registers Phase 2a trial of NAI in sepsis with persistent lymphopeniaAug 25Trial updateImmunityBio, Inc.
Washington University registers Phase Ib trial pairing Sip-T with N-803 in resistant prostate cancerAug 10Trial updateImmunityBio, Inc.nogapendekin alfa inbakicept-pmln
ImmunityBio posts Q2 2026 revenue of $50.7 million as ANKTIVA pipeline advancesAug 4Quarterly updateImmunityBio, Inc.nogapendekin alfa inbakicept-pmln
ImmunityBio wins UAE authorization for ANKTIVA in bladder cancer and lung cancerJul 30Regulatory decisionImmunityBio, Inc.nogapendekin alfa inbakicept-pmln
Sign inSign in